Pregnancy management in Behçet's disease treated with uninterrupted infliximab. Report of a case with fetal growth restriction and mini-review of the literature

The mutual impact of Behçet's disease (BD) and pregnancy is variable and still unclear. Among the safe drugs administered, the newer infliximab (IFX) was rarely experienced in pregnancy, particularly in the third trimester. The authors report a pregnancy with fetal growth restriction at 36 week...

Full description

Bibliographic Details

Published in:	Clinical and experimental obstetrics & gynecology Vol. 41; no. 2; pp. 205 - 207
Main Authors:	Mainini, G, Di Donna, M C, Esposito, E, Ercolano, S, Correa, R, Stradella, L, Della Gala, A, De Franciscis, P
Format:	Journal Article
Language:	English
Published:	Canada 01-01-2014
Subjects:	Anti-Inflammatory Agents, Non-Steroidal - therapeutic use Antibodies, Monoclonal - therapeutic use Anticoagulants - therapeutic use Behcet Syndrome - drug therapy Enoxaparin - therapeutic use Female Fetal Growth Retardation - drug therapy Humans Infant, Newborn Infliximab Labor, Induced Male Pregnancy Pregnancy Complications - drug therapy Pregnancy Trimester, Third
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!